✦ LIBER ✦

Exploiting Signal Transduction Pathways in Acute Myelogenous Leukemia

✍ Scribed by Alexander E. Perl; Martin Carroll

Book ID: 107532005
Publisher: Springer
Year: 2007
Tongue: English
Weight: 188 KB
Volume: 8
Category: Article
ISSN: 1527-2729
DOI: 10.1007/s11864-007-0043-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Signal transduction pathways in keratino

Signal transduction pathways in keratinocytes

✍ Thomas Rosenbach; Beate M. Czarnetzki 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 691 KB

TrkA signal transduction pathways in neu

TrkA signal transduction pathways in neuroblastoma

✍ Eggert, Angelika ;Ikegaki, Naohiko ;Liu, Xing-ge ;Chou, Tom T. ;Brodeur, Garrett 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 1 views

Background. Favorable neuroblastomas frequently express high levels of the TrkA receptor, and these tumors have a propensity to either differentiate or regress, but the mechanisms responsible for these two fates are unclear. Procedure. To study TrkA signal transduction in neuroblastoma (nb), we stab

Early deaths in acute myelogenous leukem

Early deaths in acute myelogenous leukemia

✍ Dr. I. E. Smith; R. Powles; H. MacD. Clink; B. Jameson; H. E. M. Kay; T. J. McEl 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 451 KB 👁 2 views

Lymphosarcoma terminating in acute myelo

Lymphosarcoma terminating in acute myelogenous leukemia

✍ Raymond B. Weiss; Richard D. Brunning; B. J. Kennedy 📂 Article 📅 1972 🏛 John Wiley and Sons 🌐 English ⚖ 350 KB 👁 2 views

Leukemic hypopyon in acute myelogenous l

Leukemic hypopyon in acute myelogenous leukemia

✍ S. Matano; T. Ohta; S. Nakamura; M. Kanno; T. Sugimoto 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 84 KB

Molecular targets in acute myelogenous l

Molecular targets in acute myelogenous leukemia

✍ Derek L Stirewalt; Soheil Meshinchi; Jerald P Radich 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 239 KB

Acute myeloid leukemia (AML) remains the most common form of leukemia and the most common cause of leukemia death. Although conventional chemotherapy can cure between 25 and 45% of AML patients, most patients will either die of relapse or die from the complications associated with treatment. Thus, m